The immunosuppressive drug cyclophosphamide was used to study the Mice infected with lactic dehydrogenase virus (LDV; reference 17) present a useful model for a study of the role of immune and nonimmune factors in controlling viremia in a chronic viral infection. The viremia in LDV-infected mice lasts for the lifetime of the mice without any overt pathology (14). Serum interferon can be detected during the first few days of infection (3, 7, 10), and neutralizing antibody can be detected after a few weeks (15, 19) ; however, the relative roles of interferon and antibody, as well as that of cellular immunity, in determining the level of viremia in this infection remain unclear.
The immunosuppressive drug cyclophosphamide was used to study the effect of immunosuppression on the degree of chronic lactic dehydrogenase virus (LDV) viremia in mice. Weekly injections of cyclophosphamide caused an increase of LDV viremia of ca. 2.5 logio 50% infectious doses per ml as compared to the viremia in the nontreated mice. This increase occurred at about the same time that the formation of antibody with a neutralization index of 2 to 3 logio per ml could be demonstrated in the serum of control mice, whereas both neutralizing antibody and sensitized (antibody-bound but infectious) virus were absent in the immunosuppressed mice. In one experiment, antibody did not reappear 28 weeks after a 24-week course of cyclophosphamide treatment. In another experiment in which the drug was given for 12 weeks, antibody appeared again in the treated mice 14 weeks after cessation of drug administration and was accompanied by a decrease in viremia. The normal decrease of early viremia during the first 2 weeks of infection in immunosuppressed mice suggests that the immune response is not the cause of this initial decrease in LDV viremia but that interferon and perhaps other nonimmune factors may be involved here. The increased viremia in the immunosuppressed mice during the later stages of infection indicates that the immune response plays an important role in partial control of chronic viremia. The quantitative correlation between the decrease in neutralizing antibody and the increase in viremia in immunosuppressed mice suggests that antibody rather than cellular immunity may be the more important immune factor in the control of chronic viremia.
Mice infected with lactic dehydrogenase virus (LDV; reference 17) present a useful model for a study of the role of immune and nonimmune factors in controlling viremia in a chronic viral infection. The viremia in LDV-infected mice lasts for the lifetime of the mice without any overt pathology (14) . Serum interferon can be detected during the first few days of infection (3, 7, 10) , and neutralizing antibody can be detected after a few weeks (15, 19) ; however, the relative roles of interferon and antibody, as well as that of cellular immunity, in determining the level of viremia in this infection remain unclear.
In an attempt to clarify the importance of immune processes in this chronic infection, we have studied the effect of a potent immunosuppressive agent, cyclophosphamide, on viremia and on the formation of neutralizing antibody and sensitized virus in LDV-infected mice.
MATERIALS AND METHODS
Animals. Random bred Swiss albino (15 to 20 g, female) mice were supplied by the animal production section of the National Institutes of Health.
Virus. The strain of LDV used was isolated from a naturally infected Ehrlich ascites carcinoma carried in CDF, mice (7) . Stock LDV was obtained from LDVfree Ehrlich ascites tumor-bearing mice, which were infected intraperitoneally with 107°50.% infectious doses (ID50) per mouse 6 to 8 days after tumor implantation. Twenty-four hours after infection, the ascitic fluid was withdrawn with an 18-gauge needle. Cells were removed by centrifugation, and the resulting supernatant fluid was frozen at -70 C. The titer of such supernatant fluids was the same as that of the blood plasma obtained from the same mice, ca. 1010°ID5o/ml.
Virus titrations. Virus titers were determined as described before (7, 9) , except that dilutions were made in Eagle's minimal essential medium with 10%o fetal bovine serum. The ID50/ml was calculated by the method of Karber (12) . 720 Antibody titrations. Sera from mice chronically infected with LDV were collected and heated at 56 C for 2 hr to inactivate residual virus. A 0.5-ml amount of each LDV antiserum was mixed with 0.5 ml of the stock LDV suspension, diluted to contain 106)°I D50/ml. The mixture was incubated at 37 C for 2 hr. A normal mouse serum control was run with each set. The neutralization index was determined by subtracting the log1o of the titer of the LDV antibody-containing samples from the logio of the titer of the sample with normal serum. Virus sensitization titrations. Sera from chronically LDV-infected mice were collected. Portions (0.1 ml) of each sample were diluted 10-fold, and 0.4 ml of this dilution was mixed with either 0.4 ml of normal rabbit serum or with anti-mouse rabbit serum (obtained from Microbiological Associates). The mixtures were incubated at 37 C for 2 hr and titered as usual. The sensitized virus index was obtained by subtraction of the oglo of the titer of the anti-mouse serum mixture from the log10 of the titer of the mixture containing the normal rabbit serum control.
Immunosuppression. Cyclophosphamide (Cytoxan) was obtained from Mead and Johnson. Before use, it was prepared at a concentration of 10 mg/ml in phosphate-buffered saline (PBS).
RESULTS
Two sets of experiments were performed to determine the effect of prolonged treatment with cyclophosphamide on the course of LDV viremia and on LDV-neutralizing antibody formation.
In the first experiment, 20 mice received 75 mg of cyclophosphamide per kg intraperitoneally 12 hr after intraperitoneal infection with 107 o ID50 of LDV per mouse and every 7 days thereafter for 24 weeks. In the second experiment, the cyclophosphamide injections were continued for 12 weeks. Fig. 1A and B. The viremia in the cyclophosphamide-treated mice was not significantly altered by the drug during the first 2 weeks of infection. The titers were somewhat lower in the first experiment (Fig. IA) and somewhat higher in the second experiment (Fig. 1B) . However, during the chronic phase, from about 3 to 4 weeks after infection until at least 28 weeks after cessation of drug treatment, the viremia of the immunosuppressed mice was ca. 1.0 to 2.5 logl0 higher. In the first experiment (Fig. IA second experiment (Fig. 1 B) in which cyclophosphamide was administered for 12 weeks, the level of viremia returned to normal 30 weeks after cessation of drug treatment.
The effect of immunosuppression on the humoral antibody response in LDV infection is presented in Table 1 . In the first experiment, cyclophosphamide treatment was continued for 24 weeks and in the second experiment it was continued for 12 weeks. No significant antibody was present in the immunosuppressed mice for at least 28 weeks after cessation of drug treatment in experiment 1 and for at least 14 weeks in experiment 2. In contrast, the neutralization index of the controls during the chronic phase varied from 1 to 3.
The effect of immunosuppression by cyclophosphamide on the degree of sensitization (formation of virus-antibody complexes which remain infectious) of LDV (in experiment 2) at various times after infection is presented in Table 2 . During the cyclophosphamide treatment no sensitized virus in significant amounts could be demonstrated. After cessation of the drug treatment, the titer of the sensitized virus in the treated group followed the pattern found for the control mice: an initial rise in titer when antibody appeared (Table 1) followed by a decline after several weeks.
DISCUSSION
Cyclophosphamide has been shown to be a potent suppressor of both cellular and humoral immunity and to potentiate a large number of viral, bacterial, and protozoal infections in mice (4, 11, 13, 20) . In our experiments, the failure of cyclophosphamide to influence viremia during the first 2 to 3 weeks of LDV infection suggests that immune processes are not primarily responsible a Neutralization index: log10 titer of controllog10 titer of antibody-containing sample.
bCyclophosphamide treatment was stopped at the indicated time. Proc. 24:318, 1965; 18) . Interferon has been demonstrated in the sera of LDV-infected mice in the first few days after infection (3, 7, 10) , and it is quite likely that interferon plays some role in the reduction of viremia in this infection. Limited support for this suggestion comes from experiments with mice, in which administration of actinomycin, which suppresses interferon formation, resulted in increased serum titers of LDV during the first week of infection (5) . Additional evidence is derived from the X-irradiation experiments reported previously (8) . Mice given wholebody X-irradiation (900 r) before infection showed greater viremia in the first week of infection then nonirradiated mice and had no demonstrable serum interferon during this period (duBuy and Johnson, unpublished data).
On the other hand, the further reduction of viremia from ca. 10-.0 to 104°ID50/ml, occurring after the first 2 16) . It has been reported that neonatal thymectomy will also result in a higher chronic viremia in LDV-infected mice (6) , and it was suggested that this was because of decreased neutralizing antibody formation. Since antibody was not measured, it is not possible to know if this suggestion is correct.
The degree of viremia during the later stages depends not only on the degree to which antibody neutralized the circulating LDV but also on the extent to which antibody formed infectious antigen-antibody complexes, thus maintaining a continual source of LDV viremia. As expected during the drug treatment, no sensitized virus could be demonstrated, supplying additional evidence that no antibody was present during immunosuppression.
It is of interest that even though viremia was potentiated, immunosuppressed mice suffered no obvious ill effects from the LDV infection. However, no histopathological studies have been carried out. Mice in the first experiment still appeared normal after over 16 months of observation, and no significant mortality has been observed in this group or in the nonimmunosuppressed LDV-infected mice.
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